The anterior chamber of the eye is a transplantation site that supports and enables visualisation of beta cell development in mice
- 1.5k Downloads
In vivo imaging of the developing pancreas is challenging due to the inaccessibility of the tissue. To circumvent this, on embryonic day 10.5 (E10.5) we transplanted a mouse developing pancreatic bud into the anterior chamber of the eye (ACE) to determine whether the eye is a useful transplant site to support pancreas development.
We transplanted an E10.5 dorsal pancreatic bud into the ACE of a syngeneic recipient mouse. Using a mouse insulin promoter–green fluorescent protein (MIP-GFP) mouse as the tissue donor, we non-invasively imaged the pancreatic bud as it develops at single beta cell resolution across time.
The transplanted pancreatic bud rapidly engrafts and vascularises when transplanted into the ACE. The pancreatic progenitor cells differentiate into exocrine and endocrine cells, including cells expressing insulin, glucagon and somatostatin. The morphology of the transplanted pancreatic bud resembles that of the native developing pancreas. Beta cells within the transplanted pancreatic bud respond to glucose in a manner similar to that of native fetal beta cells and superior to that of in vitro developed beta cells. Unlike in vitro grown pancreatic explants, pancreatic tissue developing in the ACE is vascularised, providing the developing pancreatic tissue with a milieu resembling the native situation.
Altogether, we show that the ACE is able to support growth, differentiation and function of a developing pancreatic bud across time in vivo.
KeywordsBeta cells Eye transplantation In vivo imaging Pancreas development Pancreatic islets
Anterior chamber of the eye
Embryonic day 10.5
Mouse insulin promoter–green fluorescent protein
Pancreatic and duodenal homeobox 1
One of the most attractive therapeutic approaches to battling diabetes is to transplant functional islets into a patient. However, with scarcity of tissue donors, a possible source is to derive beta cells from either embryonic stem cells or induced pluripotent stem cells in vitro. Recent articles have reported reliable protocols to produce functional human beta cells in vitro [1, 2]. However, these islets still lack bona fide complexity of intermingled heterogeneous islet cells that through paracrine interactions secrete key metabolic hormones in a highly tuned manner, thus falling short in recapitulating the functional complexities of islets. Our inability to visualise islets as they develop over time in vivo needs to be addressed so as to better understand this intricate process. A promising candidate site, not explored in islet development, is the anterior chamber of the eye (ACE) [3, 4]. Islets transplanted into the ACE maintain euglycaemia in streptozotocin-treated mouse models of diabetes, and in these mice hyperglycaemia only ensues upon enucleation (eye removal) .
In this article we show that the ACE is a useful transplantation site for supporting pancreas development in vivo. Furthermore, as the cornea is a natural body window for non-invasive, longitudinal, in vivo three-dimensional imaging, we are able to study beta cell differentiation and maturation in a living animal. Our approach combines powerful high-resolution confocal microscopy with intraocular transplantation to enable non-invasive monitoring of the same individual pancreatic bud longitudinally with the potential for direct biological/pharmacological manipulation of the local environment in the ACE  to identify key regulatory mechanisms and factors involved in pancreatic islet development.
Mice, tissue preparation and ACE transplantation
The animal experiments were approved by ethics committees at Karolinska Institutet (Stockholms Norra Försöksdjursetiska Nämnd). All mice were housed and bred in the animal facility at Karolinska Institutet at 22 ± 2°C, maintained on a 12 h/12 h light/dark cycle and fed ad libitum. Mouse insulin promoter–green fluorescent protein (MIP-GFP) male mice (B6.Cg-Tg(Ins1-EGFP)1Hara/J) on a C57BL/6-J background  were mated with C57BL/6-J females (The Jackson Laboratory, Bar Harbor, ME, USA) to generate 10.5 day embryos (E10.5), from which dorsal pancreatic buds were mechanically dissected using etched tungsten (Goodfellow Cambridge, Huntingdon, UK) tips. Buds that were damaged following mechanical dissection were excluded from the study. 8- to 10-week old C57BL/6-J male mice were used as recipients. For transplantation, the cornea was penetrated with a 27-gauge needle, and a thin glass capillary was used to transfer one pancreatic bud into the ACE of anaesthetised (2.5% isoflurane; Baxter, Deerfield, IL, USA) recipient mice. A subcutaneous injection of Temgesic (2 μg/mouse; Schering-Plough, Kenilworth, NJ, USA) was administered for postoperative analgesia.
In vitro cultures
Pancreatic buds isolated from E10.5 embryos were cultured on filters (EMD Millipore, Billerica, MA, USA) in 24-well plates (Falcon; Fisher Scientific, Hampton, NH, USA) with 400 μl of medium consisting of Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS (Invitrogen) as described previously . Tissue was cultured for 10 days at 37°C and in 5% CO2, and medium was changed every other day.
The in vivo imaging set-up was as previously described [3, 4]. To visualise blood vessels in vivo, dextran labelled with Texas Red (100 μl of 10 mg/ml; Molecular Probes, Eugene, OR, USA) was injected into the tail vein. TCS SP2 (Leica Microsystems, Wetzlar, Germany) and TCS SP5 (Leica Microsystems) confocal microscopes were used for both in vivo and immunofluorescence imaging. All antibodies were validated in-house prior to use. Primary antibodies used for immunofluorescence imaging were: guinea pig anti-insulin (1:200; Abcam, Cambridge, UK), rabbit anti-glucagon (1:100; BioGenex, Fremont, CA, USA), mouse anti-glucagon (1:100, Sigma-Aldrich, St Louis, MO, USA), rabbit anti-somatostatin (1:100; Dako, Carpinteria, CA, USA), rat anti-CD31 (1:100; BD Biosciences, Franklin Lakes, NJ, USA), rabbit anti-amylase (1:100; Sigma-Aldrich), rabbit anti-GLUT2 (1:100; in house) and rabbit anti-pancreatic and duodenal homeobox 1 (PDX1) (1:100; in house). Secondary antibodies used were appropriate combinations of Alexa 405, 488, 546, 594 and 633 (1:500; Invitrogen).
Insulin secretion analysis
ACE grafts were subjected to static incubations (30 min) in buffered solution (25 mmol/l HEPES, 125 mmol/l NaCl, 5.9 mmol/l KCl, 1.28 mmol/l CaCl2, 1.2 mmol/l MgCl2, 0.1% BSA, pH 7.4) at different glucose concentrations, with or without forskolin (10 μmol/l), and with or without KCl (25 mmol/l) (Sigma-Aldrich). Insulin in the media was measured by a two-photon fluorescence excitation microparticle fluorometry assay for insulin (ArcDia, Turku, Finland).
The ACE supports pancreatic bud development
Insulin secretion was induced in ACE-transplanted buds but not in in vitro cultured buds
So far our inability to visualise pancreatic islets as they develop in vivo has severely hampered our understanding of pancreatic islet development. Existing in vivo imaging approaches such as multiphoton microscopy require invasive surgical access to the pancreas and/or to other transplantation sites; and MRI, positron emission tomography and bioluminescence lack the spatial resolution to enable studies on islet cell development. We now demonstrate that pancreatic buds engrafted in the ACE develop similarly to the native pancreas, with cells expressing PDX1, somatostatin and glucagon. Moreover, developing islets in the ACE respond to both glucose and forskolin, similar to fetal islets . Therefore, isolated E10.5 pancreatic buds transplanted into the ACE recapitulate the development of the embryonic pancreas in terms of morphology, gene expression and function.
Our results suggest that at this developmental stage (E10.5), intrinsic signals within the pancreatic bud are sufficient to drive differentiation of pancreas-specific cells. The differentiation process within the ACE may be facilitated by the rapid revascularisation of the graft, which seems to be completed by PTD-10. A three-dimensional reconstruction of these blood vessels shows that, similar to the native pancreas, there is a high density of fine blood vessels in the islet-like endocrine clusters of the pancreas which supply the islet cells with nutrients and growth factors necessary for islet development . With appropriate reporter constructs and transgenic lines, this transplantation model provides a unique opportunity to study and identify factors regulating development of the endocrine pancreas in vivo, in real time. This, together with the possibility to manipulate the transplanted pancreatic tissue with great precision, makes this method a powerful experimental model system for developmental studies. The ability to study pancreatic islet development longitudinally in an environment resembling the native milieu may help identify mechanisms that induce maturation of the endocrine pancreas . Therefore, the ACE is a superior transplant and imaging site for studying in vivo mouse islet development and embryonic function at single-cell resolution, longitudinally and in a non-invasive manner.
We thank E. Ilegems and S. Jacob (The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden) for their technical assistance and critical reading of the manuscript.
YA was supported in part by the Agency for Science, Technology and Research (A*STAR), Singapore. In addition, this work was partly supported by a start-up grant from the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (separately for YA and P-OB), the Singapore Ministry of Education Academic Research Fund (2014-T1-001-149 (for YA)), the Swedish Diabetes Association, funds of Karolinska Institutet, the Swedish Research Council, the Novo Nordisk Foundation, the Erling-Persson Family Foundation, the Strategic Research Programme in Diabetes at Karolinska Institutet, ERC-2013-AdG 338936-BetaImage, the Knut and Alice Wallenberg Foundation, Skandia Insurance Company Ltd, the Diabetes and Wellness Foundation, the Bert von Kantzow Foundation, Svenska Diabetesstiftelsen, the Stichting af Jochnick Foundation, and the Diabetes Research Institute Foundation.
Duality of interest
P-OB is co-founder and CEO of Biocrine, an unlisted biotech company that is using the ACE technique as a research tool. HE is a co-founder, shareholder and consultant of the unlisted biotech company Betagenon AB. The other authors declare that there is no duality of interest associated with their contribution to this manuscript.
YA, JD and LS contributed to the conception and design, acquisition of data, analysis and interpretation of data and drafting of the article. XZ contributed to the acquisition of data and critical revision of the article. HE and P-OB contributed to the conception and design, and drafting of the article. All authors approved the final version to be published. P-OB is the guarantor of this work.